N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
New Approaches to Neuroblastoma Therapy Consortium
Weill Medical College of Cornell University
Wake Forest University Health Sciences
Milton S. Hershey Medical Center
Mayo Clinic
University Health Network, Toronto
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Hospital Universitario Dr. Jose E. Gonzalez
South Plains Oncology Consortium
South Plains Oncology Consortium
Inova Health Care Services
Radiation Therapy Oncology Group
South Plains Oncology Consortium
Case Comprehensive Cancer Center
University of California, San Francisco
Celgene
University of California, San Francisco
The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
M.D. Anderson Cancer Center
Montefiore Medical Center
Dana-Farber Cancer Institute
University of Washington
AbbVie
GlaxoSmithKline
Takeda
Roswell Park Cancer Institute
University of California, Davis
Hoffmann-La Roche
Alliance for Clinical Trials in Oncology
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
The Methodist Hospital Research Institute
Janssen Research & Development, LLC
Dana-Farber Cancer Institute
Grupo EspaƱol de Tumores HuƩrfanos e Infrecuentes
National Cancer Institute (NCI)
Seagen Inc.
University of Chicago
National University Hospital, Singapore
Eisai Inc.
National Cancer Institute (NCI)
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Memorial Sloan Kettering Cancer Center
National University Hospital, Singapore
H. Lee Moffitt Cancer Center and Research Institute
M.D. Anderson Cancer Center
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal